6-benzoyl-3,4-dihydroquinolin-2(1H)-one | 120067-47-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-benzoyl-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 6-benzoyl-3,4-dihydro-2(1H)-quinolinone；6-benzoyl-3,4-dihydrocarbostyril；6-Benzoyl-1,2,3,4-tetrahydroquinolin-2-one；6-benzoyl-3,4-dihydro-1H-quinolin-2-one
• CAS: 120067-47-2
• 化学式: C₁₆H₁₃NO₂
• 分子量: 251.285
• InChiKey: BGGBOXVSGGCWMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-benzoyl-3,4-dihydroquinolin-2(1H)-one 在 sodium borohydrid 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 6-(phenylhydroxymethyl)-3,4-dihydrocarbostyril
  参考文献：
  名称：

  Carbostyril derivatives as combined thromboxane synthetase and

  摘要：

  该发明涉及一种抑制哺乳动物体内同时具有高血栓素水平或前列环素/血栓素水平失衡的疾病的方法，所使用的化合物具有以下结构式：X选自以下组合之一：和一个共价键，其中R.sup.1为H、具有1-6个碳原子的烷基、可选择取代的苯基或可选择取代的苯基较低烷基，当R.sup.2为H或OH时，或者R.sup.1和R.sup.2一起代表氧代、具有1-6个碳原子的烷基亚甲基或可选择取代的苄亚甲基；R.sup.3为H或具有1-6个碳原子的烷基，R.sup.4为H且R.sup.3和R.sup.4要么相对构型，要么相对构型，或者R.sup.3和R.sup.4一起代表一个共价键；n为0-3的整数；Het为1-咪唑基或3-吡啶基；虚线代表可选择的共价键。

  公开号：

  US04792561A1
• 作为产物：
  描述：

  3,4-二氢-2(1H)-喹啉酮 生成 6-benzoyl-3,4-dihydroquinolin-2(1H)-one
  参考文献：
  名称：

  WALKER, KEITH A. M.;BRUNO, JOHN J.;MARTINEZ, GREGORY R.

  摘要：

  DOI：

文献信息

• (1H-azol-1-ylmethyl)substituted quinoline derivatives
  申请人：Hanssen Pharmaceutica

  公开号：US05185346A1

  公开（公告）日：1993-02-09

  (1H-azol-1-ylmethyl)substituted quinoline derivatives, compositions containing the same, and methods of treating mammals suffering from disorders which are characterized by an increase proliferation and/or abnormal differentation of epithelial tissues.

  (1H-唑-1-基甲基)取代喹啉衍生物，包含它们的组合物，并且治疗哺乳动物患有表皮组织增殖和/或异常分化的疾病的方法。
• (1h-azol-1-ylmethyl) substituted quinoline derivatives
  申请人：Janssen Pharmaceutica N. V.

  公开号：US05441954A1

  公开（公告）日：1995-08-15

  (1H-azol-1-ylmethyl)substituted quinoline derivatives, compositions containing the same, and methods of treating mammals suffering from disorders which are characterized by an increased proliferation and/or abnormal differentiation of epithelial tissues.

  (1H-咪唑-1-甲基)取代的喹啉衍生物，含有它们的组合物，以及治疗患有增生和/或上皮组织异常分化的疾病的哺乳动物的方法。
• (1H-azol-1-ylmethyl) substituted quinoline derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05268380A1

  公开（公告）日：1993-12-07

  (1H-azol-1-ylmethyl)substituted quinoline derivatives, compositions containing the same, and methods of treating mammals suffering from disorders which are characterized by an increased proliferation and/or abnormal differentiation of epithelial tissues.

  (1H-咪唑-1-基甲基)取代的喹啉衍生物，包含它们的组合物，以及治疗患有上皮组织增殖和/或异常分化的疾病的哺乳动物的方法。
• (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0371564A2

  公开（公告）日：1990-06-06

  Novel (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives of formula the pharmaceutical acceptable acid addition salts thereof and the stereochemically isomeric forms thereof, wherein -X1 =X2- is -CH = CH-, -CH = N-, or -N = CH-; R is hydrogen or C1-6alkyl; Y is hydrogen, C1-10alkyl, C3-7cycloalkyl, Arl, Ar2-C1-6alkyl, C2-6alkenyl or C2-6alkynyl; Z is a radical of formula which compounds are useful for treating disorders which are characterized by an excessive proliferation and/or abnormal differentiation of epithelial tissues: pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的新型(1H-唑-1-基甲基)取代的喹啉、喹唑啉或喹喔啉衍生物 其中 -X1 =X2- 是 -CH = CH-、-CH = N-或 -N = CH-；R 是氢或 C1-6 烷基；Y 是氢、C1-10 烷基、C3-7 环烷基、Arl、Ar2-C1-6 烷基、C2-6 烯基或 C2-6 烷炔基；Z 是式中的一个基团 这些化合物可用于治疗以上皮组织过度增殖和/或异常分化为特征的疾病：含有此类化合物作为活性成分的药物组合物，以及制备所述化合物和药物组合物的方法。
• 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase
  作者：Gregory R. Martinez、Keith A. M. Walker、Donald R. Hirschfeld、John J. Bruno、Diana S. Yang、Patrick J. Maloney

  DOI：10.1021/jm00082a002

  日期：1992.2

  A series of 1H-imidazol-1-yl- and 3-pyridyl-substituted 3,4-dihydroquinolin-2(1H)-ones was designed and synthesized as combined inhibitors of thromboxane (TXA2) synthase and cAMP phosphodiesterase (PDE) in human blood platelets. A number of structures, e.g. 4b, 7a, 7e, 13a, and 21-25, were superior to dazoxiben 26 as inhibitors of TXA2 synthase in in vitro ADP-induced aggregation experiments with human blood platelets. The TXA2 synthase inhibitory activity was confirmed by measurement of the prostanoid metabolites derived from C-14-labeled arachidonic acid. Three compounds (7a, 7e, and 25) demonstrated in vitro inhibition of human platelet cAMP PDE at micromolar concentrations in conjunction with their TXA2 synthase inhibitory activity. Synergistic enhancement of antiaggregatory and antithrombotic actions was expected when simultaneous stimulation of adenylate cyclase (through increased PGI2 production) and inhibition of platelet cAMP PDE were possible from the same compound. Ex vivo and in vivo experiments were conducted in rats and mice, respectively, to evaluate the effects of compounds 7e and 23 on platelet aggregation and thrombotic events within these animals. Compound 7e, which has a comparable level of TXA2 synthase (IC50 1.2-mu-M) and human platelet cAMP PDE (IC50 6.4-mu-M) inhibitory activities, was found to be orally bioavailable with a long duration of action and offered effective protection against mortality in a collagen-epinephrine-induced pulmonary thromboembolism model in mice. Significant blood pressure and heart rate effects were observed for several compounds, e.g. 7e, 9e, 13a, 13d, 18, 20, 21, and 23, when dosed orally in conscious spontaneously hypertensive rats.